Risk Scoring System for Ra-223 Discontinuation and Its Effect on Prognosis: A Retrospective Study
Year: 2021
Type: article
Study design: Observational Study
Abstract: Background/Aim: Radium-223 therapy prolongs overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastasis. Patients who are unable to complete six courses of radium-223 therapy reportedly have a poor prognosis. This study aimed to develop a risk score using the discontinuation factors of the above therapy modality. Patients and Methods: Seventy patients who received radium-223 therapy for metastatic CRPC at two Japanese Institutions were evaluated. Univariate and multivariate analyses were performed to identify the discontinuation factors and determine the risk scores. Results: The median survival time was 24.3 and 9.5 months in patients who did and did not complete the therapy, respectively. Multivariate analysis revealed haemoglobin and prostate-specific antigen as key factors. A risk score was developed using these factors, and patients were stratified into three groups. The discontinuation rate and survival after radium-223 therapy were significantly different. Conclusion: Our risk score may help evaluate the suitability of radium-223 in CRPC patients.
Source: Cancer Diagnosis & Prognosis
DOI: 10.21873/cdp.10043
Authors: HITOSHI ITO, HIROSHI YAEGASHI, YOSHIYUKI OKADA, TAKAFUMI SHIMADA, TOSHIHIDE YAMAOKA, KAZUTOSHI OKUBO, TAKASHI SAKAMOTO, ATSUSHI MIZOKAMI
Institutions: Kyoto Katsura Hospital, Kanazawa University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3213054014